Oyster Point Pharma, Inc
700 Alexander Park Drive Suite 301
Princeton, NJ 08540
United States
Tel: 609-382-9032
Website: http://ww.oysterpointrx.com/
About Oyster Point Pharma, Inc
Oyster Point is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the Trigeminal Parasympathetic Pathway (TPP) to activate the glands responsible for tear film production. The parasympathetic nervous system (PNS) is part of the involuntary nervous system responsible for regulating homeostasis, the “rest and digest” system, and is an important pathway for basal tear film production. Oyster Point Pharma is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate tear film production in patients with Dry Eye Disease (DED).
Oyster Point Pharma, named after the Oyster Point waterfront on San Francisco Bay, was founded in 2015 and is headquartered in Princeton, New Jersey.
107 articles about Oyster Point Pharma, Inc
-
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022
12/2/2022
Oyster Point Pharma, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to three new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.
-
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11/10/2022
Oyster Point Pharma, Inc. announced its financial results for the quarter ended September 30, 2022, and provided an overview of recent business highlights.
-
Eye specialist Oyster Point Pharma announced is being acquired by Viatris Inc. after Oyster’s board of directors unanimously signed off on the deal, Oyster Point announced Monday.
-
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
11/7/2022
Oyster Point Pharma, Inc., announced that it has entered into a definitive agreement under which Viatris Inc., a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
-
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2022
11/2/2022
Oyster Point Pharma, Inc., announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 14,400 shares of common stock to seven new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.
-
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
11/2/2022
Oyster Point Pharma, Inc. a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, announced that it will report third quarter 2022 financial results on Thursday, November 10, 2022, after the market close.
-
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2022
10/4/2022
Oyster Point Pharma, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 11,300 shares of common stock to three new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.
-
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
9/27/2022
Oyster Point Pharma, Inc. announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago, Illinois from September 28-29, 2022.
-
Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 07, 2022
9/7/2022
Oyster Point Pharma, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 242,600 shares of common stock to 36 new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.
-
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
8/25/2022
Oyster Point Pharma, Inc. today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.
-
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager
8/17/2022
Oyster Point Pharma, Inc. today announced that the largest Medicare Pharmacy Benefit Manager in the United States will add TYRVAYA ® Nasal Spray on its Medicare Part D formularies, effective September 1, 2022.
-
Oyster Point Pharma To Attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022
8/15/2022
Oyster Point Pharma, Inc. today announced that Dr. Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Oyster Point Pharma, will attend the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.
-
Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8/11/2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), today announced its financial results for the quarter ended June 30, 2022, and provided an overview of recent business highlights.
-
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
8/8/2022
Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022, after the market close.
-
Although the company promised strong sales-based resources for the launch of dry eye drug Tyrvaya, the streamlining plan will include laying off up to 50 employees.
-
Oyster Point Pharma Announces Operating Expense Streamlining Plan
6/28/2022
Oyster Point Pharma, Inc. announced it will implement an operating expense streamlining plan that will include a reduction of employee and non-employee expenses across the organization.
-
Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®
6/15/2022
Oyster Point Pharma, Inc. announced that a scientific poster featuring data from pivotal clinical trials of TYRVAYA® Nasal Spray has been selected for the Top 5 Poster Session at the American Optometric Association's Optometry's Meeting® being held on June 15-18 in Chicago, Illinois.
-
Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/5/2022
Oyster Point Pharma, Inc. announced its financial results for the quarter ended March 31, 2022, and provided an overview of recent business highlights.
-
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET
5/3/2022
Oyster Point Pharma, Inc. announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the market close.
-
Oyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022
4/27/2022
Oyster Point Pharma, Inc. today announced the presentation of data analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022, being held on May 1-4.